Five Synexus Sites Randomise More Than 1300 Patients in Three Weeks
MANCHESTER, England--(BUSINESS WIRE)--Nov 5, 2008 - Synexus(R) recently randomised more than 1300 patients in a vaccine study at five sites across Europe over a three week period, as part of a global programme.
The Synexus(R) sites were the first to achieve its upwardly revised target due to a sophisticated patient recruitment operation. Synexus(R) has developed a number of tools to ensure that it meets and often exceeds its randomisation targets. In the vaccine study Synexus(R)'s huge database of patients wanting to take part in a clinical study was an important component.
Michael Fort CEO of Synexus(R) commented: "We are developing a world class patient recruitment organisation which uses a wide variety of tools to find the right patient for each study. These tools include our huge database, editorials, working with patient groups, advertising, high foot fall promotion events and in countries such as India and South Africa we have established fixed and mobile outreach clinics."
Synexus(R) is continuing to expand its own network of clinical research centres with nine new clinical centres planned to be opened within the next six months. This will bring the number of centres to 20 in eight countries.
Synexus(R) background
Synexus(R) headquartered in Manchester, England, is the world's leading multi-national company dedicated to the recruitment and running of clinical trials.
Synexus(R) recruits participants for clinical trials on behalf of pharmaceutical, biotech and CROs. The clinical trials are then run and managed by Synexus(R) at 11 clinical research centres across the UK, Poland, Hungary, Bulgaria, India and South Africa.
Synexus(R) pioneered the running of clinical trials at clinical research centres against the traditional method of contracting with primary care physicians, who on average only recruit and manage five patients each.
Synexus(R) currently has more than ten thousand patients enrolled in clinical trials.
Contact
Vane Percy & Roberts for Synexus®
Simon Vane Percy
Office: +44 (0) 1737 821 890/892
Mobile: +44 (0) 7710 005910
Home: +44 (0) 1883 724505
(e) simon@vanepercy.com
